Stonepine Capital Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Stonepine Capital Management’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,914,938	Closed	-$19.2M	–	37
2021 Q3	$19.2M	Buy	3,914,938 +1,220,643	+45%	+$5.93M	8.75%	3
2021 Q2	$14.2M	Sell	2,694,295 -723,984	-21%	-$3.75M	7.44%	4
2021 Q1	$16.4M	Buy	3,418,279 +2,609,848	+323%	+$13.6M	8.86%	2
2020 Q4	$3.5M	Buy	808,431 +150,964	+23%	+$646K	2.68%	11
2020 Q3	$2.71M	Sell	657,467 -100,237	-13%	-$388K	2.82%	10
2020 Q2	$1.94M	Sell	757,704 -405,172	-35%	-$1.19M	3.76%	10
2020 Q1	$3.36M	Sell	1,162,876 -1,078,363	-48%	-$4.83M	3.55%	13
2019 Q4	$8.49M	Buy	2,241,239 +1,490,227	+198%	+$7.13M	5.92%	5
2019 Q3	$3.84M	Sell	751,012 -672,566	-47%	-$4.15M	3.73%	12
2019 Q2	$8.83M	Buy	1,423,578 +439,249	+45%	+$2.53M	6.08%	5
2019 Q1	$7M	Buy	+984,329	New	+$8.85M	4.03%	8

Stonepine Capital Management's ADMS Position: Q4 2021 in Review

Stonepine Capital Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 3,914,938 shares — an estimated $19.2M sold.

Stonepine Capital Management first reported a position in ADMS in Q1 2019 and held it in 11 quarters. The position peaked at $19.2M in Q3 2021. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

Stonepine Capital Management reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Stonepine Capital Management sold 3,914,938 Adamas Pharmaceuticals shares in Q4 2021, an estimated $19.2M.
Stonepine Capital Management first reported a position in Adamas Pharmaceuticals in Q1 2019 and held it in 11 quarters.
Stonepine Capital Management's Adamas Pharmaceuticals position peaked at $19.2M in Q3 2021.
0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on Stonepine Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.